Imeik Technology Development Co Ltd
Company Profile
Business description
Imeik Technology Development is a leading Chinese medical aesthetics company, best known for its portfolio of hyaluronic acid-based solutions and gel injectable products. Founded in 2004 and headquartered in Beijing, the company has built its reputation on product innovation and a differentiated strategy, enabling it to rank first in China with a market share by value exceeding 20% in 2024. In 2025, Imeik acquired a controlling stake (approximately 60%) in South Korea’s Regen Biotech through a joint venture with an investment fund. Presently, almost all of Imeik’s revenue is derived domestically in China.
Contact
No. 92A, Jianguo Road
21st Floor, Tower C, Shimao Tower
Chaoyang District
Beijing100022
CHNT: +86 1085809026
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
1,458
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |